TRAP-6 peptide

TRAP-6 peptide

• COA/MS/HPLC Report
• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

SFLLRN

H-Ser-Phe-Leu-Leu-Arg-Asn-OH

6

97.31%

C₃₄H₅₆N₁₀O₉

748.86

141136-83-6

Synthetic

Powder

SFLLRN corresponds to residues 42-47 of the thrombin receptor. The hexapeptide acts as a thrombin receptor activator. It caused half-maximal platelet aggregation at approx. 0.8 uM and was 5 times more potent than the parent peptide H-8105. In addition, SFLLRN is effective in causing tyrosine phosphorylation, inhibition of cAMP formation, and an increase in cytosolic Ca2+.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• R.R.Vassallo, Jr. et al., J. Biol. Chem., 267, 6081 (1992)
• L.F.Brass et al., J. Biol. Chem., 269, 2943 (1994)
• R.Kaufmann et al., NeuroReport, 9, 709 (1998)
• B.A.Olson et al., Pharmacology, 58, 200 (1999)
• R.Kaufmann et al., J. Neurooncol., 42, 131 (1999)
• H.Andersen et al., Proc. Natl. Acad. Sci. USA, 96, 11189 (1999)
• C.-C.Wu et al., Br. J. Pharmacol., 130, 1289 (2000)
• H.Shankar et al., Blood, 104, 1335 (2004)

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.